Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Clovis

Bristol-Myers Squibb (BMS) building

BMS to explore new options for its immuno-oncology drug Opdivo

Partners with PsiOxis to research its use with enadenotucirev

- PMLiVE

Merck & Co signs cancer vaccines research deal for Keytruda

Will work on range of personalised vaccines to complement its blockbuster

Bristol-Myers Squibb (BMS) building

Speedy NICE appraisal backs BMS’ Opdivo/Yervoy combination

But HTA body doesn't find Roche's Cotellic/Zelboraf cost-effective

- PMLiVE

Trial backs Keytruda use first-line in lung cancer

Suggests Merck & Co’s drug is more effective than chemotherapy for NSCLC patients

Roche Basel Switzerland

Roche’s Tecentriq works as first-line bladder cancer therapy

New trial data presented at ASCO supports wider use of the drug

Roche Basel Switzerland

Roche gets first approval for PD-L1 inhibitor Tecentriq

Expects to launch bladder cancer treatment within the next two weeks

National Institute for Health and Care Excellence NICE logo

NICE rejects Opdivo for lung cancer once again

Says PD-1 inhibitor is too expensive to be used routinely

Bristol-Myers Squibb (BMS) building

BMS gets two new cancer approvals in Europe

Empliciti, and Opdivo and Yervoy inhibitor combination get the green light

Bristol-Myers Squibb (BMS) building

BMS claims 80% market share for Opdivo in US

New indications and label updates boost the cancer immunotherapy’s market position

Bristol Myers Squibb logo

Opdivo boosts survival in head and neck cancer by 30%

Pivotal trial of BMS’ PD-1 inhibitor shows "significant benefit" in overall survival

Sanofi reception

Sanofi takeover bid rebuffed by Medivation

Had sought to boost its portfolio by acquiring the US cancer therapies firm

Bristol-Myers Squibb (BMS) building

BMS’ Opdivo gets two new indications in Europe

Receives green light as lung and kidney cancer immunotherapy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links